| Active substance | enzalutamide |
| Holder | Astellas Pharm B.V.a |
| Status | Running |
| Indication | As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 19/02/2025 |